Nuocheng Jianhua (688428.SH): The study on the treatment of non-segmental vitiligo II with Soficitinib (ICP-332) has reached the primary endpoint.

Smart Finance APP News, Nuocheng Jianhua (688428.SH) announced that the company's independently developed new generation high-selective oral tyrosine kinase 2 (referred to as "TYK2") inhibitor soficitinib (ICP-332) for the treatment of non-segmental vitiligo (NSV) patients has successfully achieved the primary endpoint in Phase II/III adaptive clinical trials, with positive top-line results.